We report here that xenograft tumor growth of an oncogenic HRASG12V-transformed human cell line engineered to express activated PI3K is diminished upon knockdown of endogenous wild-type KRAS, and that this effect was rescued by re-expressing the wild-type, but not the C118S-mutant KRAS. Here, KRAS is linked to neoplasm.